JP2014526244A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014526244A5 JP2014526244A5 JP2014529143A JP2014529143A JP2014526244A5 JP 2014526244 A5 JP2014526244 A5 JP 2014526244A5 JP 2014529143 A JP2014529143 A JP 2014529143A JP 2014529143 A JP2014529143 A JP 2014529143A JP 2014526244 A5 JP2014526244 A5 JP 2014526244A5
- Authority
- JP
- Japan
- Prior art keywords
- cells
- antigen
- cell population
- party
- days
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 210000004027 cell Anatomy 0.000 claims 71
- 238000000034 method Methods 0.000 claims 36
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 claims 11
- 239000000427 antigen Substances 0.000 claims 10
- 102000036639 antigens Human genes 0.000 claims 10
- 108091007433 antigens Proteins 0.000 claims 10
- 210000004443 dendritic cell Anatomy 0.000 claims 10
- 102000003812 Interleukin-15 Human genes 0.000 claims 9
- 102100030703 Interleukin-22 Human genes 0.000 claims 9
- 102100021592 Interleukin-7 Human genes 0.000 claims 9
- 108010002586 Interleukin-7 Proteins 0.000 claims 9
- 210000001744 T-lymphocyte Anatomy 0.000 claims 9
- 238000012258 culturing Methods 0.000 claims 9
- 210000001519 tissue Anatomy 0.000 claims 9
- 230000000779 depleting effect Effects 0.000 claims 7
- 201000010099 disease Diseases 0.000 claims 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 7
- 238000002054 transplantation Methods 0.000 claims 7
- 210000003958 hematopoietic stem cell Anatomy 0.000 claims 6
- 210000003071 memory t lymphocyte Anatomy 0.000 claims 6
- 230000000694 effects Effects 0.000 claims 4
- 208000024908 graft versus host disease Diseases 0.000 claims 4
- 210000001165 lymph node Anatomy 0.000 claims 4
- 238000004519 manufacturing process Methods 0.000 claims 4
- 101000581981 Homo sapiens Neural cell adhesion molecule 1 Proteins 0.000 claims 3
- 102100027347 Neural cell adhesion molecule 1 Human genes 0.000 claims 3
- 230000001464 adherent effect Effects 0.000 claims 3
- 210000000612 antigen-presenting cell Anatomy 0.000 claims 3
- 230000010261 cell growth Effects 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 230000003614 tolerogenic effect Effects 0.000 claims 3
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 claims 2
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 claims 2
- 102100026878 Interleukin-2 receptor subunit alpha Human genes 0.000 claims 2
- 230000000735 allogeneic effect Effects 0.000 claims 2
- 239000003795 chemical substances by application Substances 0.000 claims 2
- 208000032839 leukemia Diseases 0.000 claims 2
- 230000003211 malignant effect Effects 0.000 claims 2
- 210000000056 organ Anatomy 0.000 claims 2
- 210000004738 parenchymal cell Anatomy 0.000 claims 2
- 102000004169 proteins and genes Human genes 0.000 claims 2
- 108090000623 proteins and genes Proteins 0.000 claims 2
- 230000003612 virological effect Effects 0.000 claims 2
- 208000023275 Autoimmune disease Diseases 0.000 claims 1
- 101001018097 Homo sapiens L-selectin Proteins 0.000 claims 1
- 102100033467 L-selectin Human genes 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 230000001580 bacterial effect Effects 0.000 claims 1
- 230000003394 haemopoietic effect Effects 0.000 claims 1
- 210000002216 heart Anatomy 0.000 claims 1
- 238000000338 in vitro Methods 0.000 claims 1
- 210000000936 intestine Anatomy 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 210000000496 pancreas Anatomy 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 210000000952 spleen Anatomy 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161532172P | 2011-09-08 | 2011-09-08 | |
| US61/532,172 | 2011-09-08 | ||
| PCT/IL2012/050354 WO2013035099A1 (en) | 2011-09-08 | 2012-09-06 | Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014526244A JP2014526244A (ja) | 2014-10-06 |
| JP2014526244A5 true JP2014526244A5 (enExample) | 2015-10-29 |
| JP6196620B2 JP6196620B2 (ja) | 2017-09-13 |
Family
ID=47003163
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014529143A Active JP6196620B2 (ja) | 2011-09-08 | 2012-09-06 | 抗第三者セントラルメモリーｔ細胞、その作製方法ならびに移植および疾患処置におけるその使用 |
Country Status (14)
| Country | Link |
|---|---|
| US (3) | US20140212398A1 (enExample) |
| EP (1) | EP2753351B1 (enExample) |
| JP (1) | JP6196620B2 (enExample) |
| KR (1) | KR102073901B1 (enExample) |
| CN (1) | CN103930130B (enExample) |
| AU (1) | AU2012305931B2 (enExample) |
| BR (1) | BR112014005355B1 (enExample) |
| CA (1) | CA2848121C (enExample) |
| ES (1) | ES2640813T3 (enExample) |
| MX (1) | MX351226B (enExample) |
| RU (1) | RU2636503C2 (enExample) |
| SG (1) | SG11201400513PA (enExample) |
| WO (1) | WO2013035099A1 (enExample) |
| ZA (1) | ZA201401993B (enExample) |
Families Citing this family (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010049935A1 (en) * | 2008-10-30 | 2010-05-06 | Yeda Research And Development Co. Ltd. | Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment |
| CA2772076A1 (en) | 2009-08-24 | 2011-03-10 | Baylor College Of Medicine | Generation of ctl lines with specificity against multiple tumor antigens or multiple viruses |
| ES2589678T3 (es) | 2010-09-08 | 2016-11-15 | Yeda Research And Development Co. Ltd. | Uso de linfocitos T de memoria central anti-terceros para el tratamiento anti-leucemia/linfoma |
| SG11201400513PA (en) | 2011-09-08 | 2014-06-27 | Yeda Res & Dev | Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment |
| BR112014014591A8 (pt) | 2011-12-12 | 2017-07-04 | Baylor College Medicine | processo para a expansão in vitro de células t específicas de antígeno, produto de células t autólogas ou alogênicas expandidas, composição farmacêutica, e, método de tratamento de um paciente, e, usos de uma linhagem de células engenheirada, de células dendríticas pulsadas com misturas de antígeno-peptídeo, de t-apcs pulsadas com misturas de antígeno-peptídeo/peptídeo, e de misturas de antígeno-peptídeo com pbmcs |
| GB201121308D0 (en) | 2011-12-12 | 2012-01-25 | Cell Medica Ltd | Process |
| EP2812431B1 (en) | 2012-02-09 | 2019-07-17 | Baylor College Of Medicine | Pepmixes to generate multiviral ctls with broad specificity |
| CN110241086A (zh) * | 2012-06-11 | 2019-09-17 | 威尔逊沃夫制造公司 | 用于过继细胞疗法的改进的细胞培养方法 |
| WO2016168595A1 (en) * | 2015-04-17 | 2016-10-20 | Barrett David Maxwell | Methods for improving the efficacy and expansion of chimeric antigen receptor-expressing cells |
| CN104946588A (zh) * | 2015-07-07 | 2015-09-30 | 英普乐孚生物技术(上海)有限公司 | 一种抗原特异性t淋巴细胞的分离和高效扩增培养方法 |
| AU2016291825B2 (en) * | 2015-07-16 | 2022-08-11 | Yeda Research And Development Co. Ltd. | Genetically modified anti-third party central memory T cells and use of same in immunotherapy |
| US10829735B2 (en) | 2015-07-21 | 2020-11-10 | The Trustees Of The University Of Pennsylvania | Methods for improving the efficacy and expansion of immune cells |
| US11167024B2 (en) | 2015-09-18 | 2021-11-09 | Baylor College Of Medicine | Immunogenic antigen identification from a pathogen and correlation to clinical efficacy |
| US10691773B2 (en) | 2015-12-30 | 2020-06-23 | General Electric Company | Cell processing techniques |
| CN109715196A (zh) | 2016-06-13 | 2019-05-03 | 转矩医疗股份有限公司 | 用于促进免疫细胞功能的组合物和方法 |
| CN117731763A (zh) * | 2016-06-24 | 2024-03-22 | 麦克马斯特大学 | 过继细胞转移与溶瘤病毒组合疗法 |
| EP3475414B1 (en) | 2016-06-27 | 2025-03-26 | Yeda Research and Development Co. Ltd | Veto cells generated from memory t cells |
| US10751368B2 (en) | 2017-01-18 | 2020-08-25 | Yeda Research And Development Co. Ltd. | Methods of transplantation and disease treatment |
| ES3064681T3 (en) | 2017-01-18 | 2026-04-28 | Yeda Res & Dev | Genetically modified veto cells and use of same in immunotherapy |
| EP3572502B1 (en) * | 2017-01-20 | 2023-01-11 | Kyoto University | Method for producing cd8alpha +beta + cytotoxic t cells |
| CN118662615A (zh) | 2017-03-15 | 2024-09-20 | 浩康生物系统公司 | 用于造血干细胞移植的组合物和方法 |
| CA3074826A1 (en) | 2017-09-05 | 2019-03-14 | Torque Therapeutics, Inc. | Therapeutic protein compositions and methods of making and using the same |
| BR112020005552A2 (pt) * | 2017-09-20 | 2020-10-27 | Neximmune, Inc. | composições de células compreendendo células t específicas de antígeno para terapia adotiva |
| CN108165529B (zh) * | 2017-12-28 | 2021-07-16 | 北昊干细胞与再生医学研究院有限公司 | 中枢记忆性t细胞体及其外培养方法 |
| US12180457B2 (en) * | 2018-02-06 | 2024-12-31 | Seattle Children's Hospital | Closed-system manufacturing process for CAR-T cells |
| US11925640B2 (en) | 2018-06-22 | 2024-03-12 | Mayo Foundation For Medical Education And Research | Methods and materials for improving arteriovenous fistula maturation and maintaining arteriovenous fistula functionality |
| WO2020010259A1 (en) * | 2018-07-06 | 2020-01-09 | Mayo Foundation For Medical Education And Research | Methods and materials for improving transplant outcomes |
| WO2020032780A1 (ko) * | 2018-08-10 | 2020-02-13 | 주식회사 유틸렉스 | 암항원 특이적 세포독성 t세포 |
| CN109628396B (zh) * | 2019-01-24 | 2021-03-26 | 清华大学 | 记忆性淋巴细胞群在肝癌治疗中的应用 |
| EP4009991A4 (en) * | 2019-08-06 | 2023-09-13 | Yeda Research and Development Co. Ltd | ANTI-VIRAL CENTRAL MEMORY CD8+ VETO CELLS IN HAPLOIDENTIC STEM CELL TRANSPLANTATION |
| AU2020379319A1 (en) * | 2019-11-05 | 2022-06-23 | Yeda Research And Development Co. Ltd. | Use of veto cells in treatment of T cell mediated autoimmune diseases |
| BR112022008700A2 (pt) * | 2019-11-05 | 2022-07-19 | Yeda Res & Dev | Método para tratar ou prevenir uma doença falciforme, e, transplante de células hematopoiéticas imaturas e uma quantidade terapeuticamente eficaz de uma população isolada de células anti-terceiros não indutoras de doença do enxerto versus hospedeiro |
| WO2021230304A1 (ja) * | 2020-05-13 | 2021-11-18 | Ａｇｃ株式会社 | ヒトプロフェッショナル抗原提示細胞の製造方法 |
| IL300470A (en) * | 2020-08-11 | 2023-04-01 | Yeda res & development co ltd | Veto type CAR-T cells |
| CN116083359A (zh) * | 2021-11-05 | 2023-05-09 | 瑞创生物技术有限公司 | 一种体外大规模扩增富含Tscm和Tcm的双阴性T细胞的方法 |
| US20230287448A1 (en) * | 2022-01-20 | 2023-09-14 | 3T Biosciences, Inc. | T cell receptor (tcr) compositions and methods for optimizing antigen reactive t-cells |
| US12584107B2 (en) | 2022-01-20 | 2026-03-24 | 3T Biosciences, Inc. | T cell receptor (TCR) compositions and methods for optimizing antigen reactive T-cells |
| WO2023154761A2 (en) * | 2022-02-08 | 2023-08-17 | The Wistar Institute Of Anatomy And Biology | Modified primary immune cells for induction or enhancement of immunotherapy |
Family Cites Families (75)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL154600B (nl) | 1971-02-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen. |
| NL154598B (nl) | 1970-11-10 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van laagmoleculire verbindingen en van eiwitten die deze verbindingen specifiek kunnen binden, alsmede testverpakking. |
| NL154599B (nl) | 1970-12-28 | 1977-09-15 | Organon Nv | Werkwijze voor het aantonen en bepalen van specifiek bindende eiwitten en hun corresponderende bindbare stoffen, alsmede testverpakking. |
| US3901654A (en) | 1971-06-21 | 1975-08-26 | Biological Developments | Receptor assays of biologically active compounds employing biologically specific receptors |
| US3853987A (en) | 1971-09-01 | 1974-12-10 | W Dreyer | Immunological reagent and radioimmuno assay |
| US3867517A (en) | 1971-12-21 | 1975-02-18 | Abbott Lab | Direct radioimmunoassay for antigens and their antibodies |
| NL171930C (nl) | 1972-05-11 | 1983-06-01 | Akzo Nv | Werkwijze voor het aantonen en bepalen van haptenen, alsmede testverpakkingen. |
| US3850578A (en) | 1973-03-12 | 1974-11-26 | H Mcconnell | Process for assaying for biologically active molecules |
| US3935074A (en) | 1973-12-17 | 1976-01-27 | Syva Company | Antibody steric hindrance immunoassay with two antibodies |
| US3996345A (en) | 1974-08-12 | 1976-12-07 | Syva Company | Fluorescence quenching with immunological pairs in immunoassays |
| US4034074A (en) | 1974-09-19 | 1977-07-05 | The Board Of Trustees Of Leland Stanford Junior University | Universal reagent 2-site immunoradiometric assay using labelled anti (IgG) |
| US3984533A (en) | 1975-11-13 | 1976-10-05 | General Electric Company | Electrophoretic method of detecting antigen-antibody reaction |
| US4098876A (en) | 1976-10-26 | 1978-07-04 | Corning Glass Works | Reverse sandwich immunoassay |
| US4879219A (en) | 1980-09-19 | 1989-11-07 | General Hospital Corporation | Immunoassay utilizing monoclonal high affinity IgM antibodies |
| US5011771A (en) | 1984-04-12 | 1991-04-30 | The General Hospital Corporation | Multiepitopic immunometric assay |
| US4666828A (en) | 1984-08-15 | 1987-05-19 | The General Hospital Corporation | Test for Huntington's disease |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4801531A (en) | 1985-04-17 | 1989-01-31 | Biotechnology Research Partners, Ltd. | Apo AI/CIII genomic polymorphisms predictive of atherosclerosis |
| US5272057A (en) | 1988-10-14 | 1993-12-21 | Georgetown University | Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase |
| US5192659A (en) | 1989-08-25 | 1993-03-09 | Genetype Ag | Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes |
| US5281521A (en) | 1992-07-20 | 1994-01-25 | The Trustees Of The University Of Pennsylvania | Modified avidin-biotin technique |
| US6803036B1 (en) | 1998-03-03 | 2004-10-12 | University Of Southern California | Use of cytokines, cells and mitogens to inhibit graft versus host disease |
| EP1061949B1 (en) | 1998-03-03 | 2009-07-15 | University of Southern California | Cytokines and mitogens to inhibit graft-versus-host disease |
| AU2101600A (en) | 1998-12-24 | 2000-07-31 | Novartis Ag | Porcine cells incapable of expressing cd40 antigen, for xenotransplantation |
| US6544506B2 (en) | 2000-01-05 | 2003-04-08 | Yeda Research & Development Co. Ltd. | Veto cells effective in preventing graft rejection and devoid of graft versus host potential |
| ATE460475T1 (de) * | 2000-04-11 | 2010-03-15 | Univ Southern California | Methode zur verhinderung der transplantatabstossung unter verwendung von tgf- beta zur induktion von t-suppressorzellen |
| US7094874B2 (en) | 2000-05-26 | 2006-08-22 | Bristol-Myers Squibb Co. | Soluble CTLA4 mutant molecules |
| CA2630062C (en) | 2000-07-03 | 2014-10-14 | Bristol-Myers Squibb Company | Methods for treating graft versus host disease and immune disorders associated with rejection using a soluble ctla4 molecule |
| US20040022787A1 (en) | 2000-07-03 | 2004-02-05 | Robert Cohen | Methods for treating an autoimmune disease using a soluble CTLA4 molecule and a DMARD or NSAID |
| WO2002043651A2 (en) * | 2000-11-30 | 2002-06-06 | Yeda Research And Development Co. Ltd. | Methods of utilizing cultured non-gvhd inducing t lymphocytes to treat disease |
| EP1241249A1 (en) * | 2001-03-12 | 2002-09-18 | Gerold Schuler | CD4+CD25+regulatory T cells from human blood |
| ATE390931T1 (de) | 2001-05-23 | 2008-04-15 | Bristol Myers Squibb Co | Verfahren zum schützen eines allogenen inseltransplantats mit löslichen ctla4- mutationsmolekülen |
| US20030147859A1 (en) | 2001-06-18 | 2003-08-07 | Yair Reisner | Methods of utilizing cultured hematopoietic progenitor cells for inducing immunological tolerance |
| US20040136972A1 (en) | 2001-09-07 | 2004-07-15 | Yeda Research And Development Co. Ltd. | Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues |
| US7745140B2 (en) | 2002-01-03 | 2010-06-29 | The Trustees Of The University Of Pennsylvania | Activation and expansion of T-cells using an engineered multivalent signaling platform as a research tool |
| EP1549277A4 (en) | 2002-05-22 | 2007-09-05 | Cleveland Clinic Foundation | INDUCING AND MAINTAINING COMPLEX TISSUE ALLOGRAFT TOLERANCE |
| IL165425A0 (en) | 2004-11-28 | 2006-01-15 | Yeda Res & Dev | Methods of treating disease by transplantation of developing allogeneic or xenogeneic organs or tissues |
| NZ545314A (en) | 2003-08-04 | 2009-03-31 | Bristol Myers Squibb Co | Methods for treating cardiovascular disease using a soluble CTLA4 molecule |
| WO2005067956A2 (en) | 2004-01-15 | 2005-07-28 | Novo Nordisk A/S | Use of interleukin-21 for the treatment of autoimune diseases and allograft rejection |
| KR100845354B1 (ko) | 2004-03-26 | 2008-07-09 | 화이자 프로덕츠 인코포레이티드 | 항－ｃｔｌａ－4 항체의 용도 |
| WO2006041763A1 (en) | 2004-10-04 | 2006-04-20 | Novartis Ag | Renin inhibitors for treating transplantation induced diseases |
| EP1814580B1 (en) * | 2004-11-24 | 2016-08-10 | Fred Hutchinson Cancer Research Center | Methods of using il-21 for adoptive immunotherapy and identification of tumor antigens |
| PL1868635T3 (pl) | 2005-04-06 | 2017-10-31 | Bristol Myers Squibb Co | Metody leczenia zaburzeń immunologicznych związanych z transplantacją narządów rozpuszczalnymi zmutowanymi cząsteczkami CTLA4 |
| EP2514315A3 (en) * | 2005-08-24 | 2012-11-07 | Yeda Research and Development Co. Ltd. | Universal donor-derived tolerogenic cells for inducing non-syngeneic transplantation tolerance |
| GB0605217D0 (en) | 2006-03-15 | 2006-04-26 | Novartis Ag | Method and compositions for assessing acute rejection |
| GB0606776D0 (en) | 2006-04-03 | 2006-05-10 | Novartis Pharma Ag | Predictive biomarkers for chronic allograft nephropathy |
| US20080131415A1 (en) | 2006-11-30 | 2008-06-05 | Riddell Stanley R | Adoptive transfer of cd8 + t cell clones derived from central memory cells |
| US20100254958A1 (en) | 2007-10-24 | 2010-10-07 | Anne Letsch | Antigen-Specific T-Cell Preparations from Bone Marrow |
| US8200915B2 (en) | 2008-08-22 | 2012-06-12 | Cadence Design Systems, Inc. | Management of very large streaming data sets for efficient writes and reads to and from persistent storage |
| WO2010049935A1 (en) * | 2008-10-30 | 2010-05-06 | Yeda Research And Development Co. Ltd. | Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment |
| US9211321B2 (en) | 2009-10-27 | 2015-12-15 | Immunicum Ab | Method for proliferation of antigen-specific T cells |
| EP2566954B2 (en) | 2010-05-04 | 2022-11-02 | Yeda Research and Development Co. Ltd. | Immunotherapy using redirected allogeneic cells |
| ES2589678T3 (es) | 2010-09-08 | 2016-11-15 | Yeda Research And Development Co. Ltd. | Uso de linfocitos T de memoria central anti-terceros para el tratamiento anti-leucemia/linfoma |
| EP2614083A2 (en) | 2010-09-08 | 2013-07-17 | Yeda Research and Development Co. Ltd | An immunosuppressive drug combination for a stable and long term engraftment |
| WO2012129514A1 (en) | 2011-03-23 | 2012-09-27 | Fred Hutchinson Cancer Research Center | Method and compositions for cellular immunotherapy |
| CN107320734A (zh) | 2011-04-29 | 2017-11-07 | 西莱克塔生物科技公司 | 从合成纳米载体中控制释放免疫抑制剂 |
| SG11201400513PA (en) | 2011-09-08 | 2014-06-27 | Yeda Res & Dev | Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment |
| WO2013084190A1 (en) | 2011-12-08 | 2013-06-13 | Yeda Research And Development Co. Ltd. | Mammalian fetal pulmonary cells and therapeutic use of same |
| RU2657758C2 (ru) | 2011-12-22 | 2018-06-15 | Иеда Рисеч Энд Девелопмент Ко. Лтд. | Комбинированная терапия для стабильного и долговременного приживления трансплантата |
| LT2884999T (lt) | 2012-08-20 | 2021-04-12 | Fred Hutchinson Cancer Research Center | Ląstelinės imunoterapijos būdas ir kompozicijos |
| US10316289B2 (en) | 2012-09-06 | 2019-06-11 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Methods of producing T memory stem cell populations |
| WO2014059173A2 (en) | 2012-10-10 | 2014-04-17 | Sangamo Biosciences, Inc. | T cell modifying compounds and uses thereof |
| US9499855B2 (en) | 2013-03-14 | 2016-11-22 | Elwha Llc | Compositions, methods, and computer systems related to making and administering modified T cells |
| EP2970372B1 (en) | 2013-03-15 | 2020-09-30 | Celgene Corporation | Modified t lymphocytes |
| EP3789487A1 (en) | 2013-04-03 | 2021-03-10 | Memorial Sloan Kettering Cancer Center | Effective generation of tumor-targeted t-cells derived from pluripotent stem cells |
| LT3148579T (lt) | 2014-05-28 | 2021-05-25 | Agenus Inc. | Anti-gitr antikūnai ir jų panaudojimo būdai |
| RU2716716C2 (ru) | 2014-10-27 | 2020-03-16 | Фред Хатчинсон Кэнсер Рисёрч Сентер | Композиции и способы для бустинга эффективности адоптивной клеточной иммунотерапии |
| KR102546296B1 (ko) | 2014-10-31 | 2023-06-21 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 변형된 t 세포에서 유전자 발현의 변경 및 그의 용도 |
| KR102349677B1 (ko) | 2015-05-28 | 2022-01-12 | 카이트 파마 인코포레이티드 | T 세포 요법을 위해 환자를 컨디셔닝하는 방법 |
| AU2016291825B2 (en) | 2015-07-16 | 2022-08-11 | Yeda Research And Development Co. Ltd. | Genetically modified anti-third party central memory T cells and use of same in immunotherapy |
| JP7082051B2 (ja) | 2016-01-11 | 2022-06-07 | アルモ・バイオサイエンシーズ・インコーポレイテッド | 抗原特異的ｃｄ８＋ｔ細胞の産生におけるインターロイキン－１０及びその使用方法 |
| WO2017203520A1 (en) | 2016-05-22 | 2017-11-30 | Yeda Research And Development Co. Ltd. | Methods of using pulmonary cells for transplantation and induction of tolerance |
| EP3475414B1 (en) | 2016-06-27 | 2025-03-26 | Yeda Research and Development Co. Ltd | Veto cells generated from memory t cells |
| US10751368B2 (en) | 2017-01-18 | 2020-08-25 | Yeda Research And Development Co. Ltd. | Methods of transplantation and disease treatment |
| ES3064681T3 (en) | 2017-01-18 | 2026-04-28 | Yeda Res & Dev | Genetically modified veto cells and use of same in immunotherapy |
-
2012
- 2012-09-06 SG SG11201400513PA patent/SG11201400513PA/en unknown
- 2012-09-06 ES ES12769743.1T patent/ES2640813T3/es active Active
- 2012-09-06 WO PCT/IL2012/050354 patent/WO2013035099A1/en not_active Ceased
- 2012-09-06 RU RU2014110897A patent/RU2636503C2/ru active
- 2012-09-06 CA CA2848121A patent/CA2848121C/en active Active
- 2012-09-06 EP EP12769743.1A patent/EP2753351B1/en active Active
- 2012-09-06 KR KR1020147009267A patent/KR102073901B1/ko active Active
- 2012-09-06 MX MX2014002771A patent/MX351226B/es active IP Right Grant
- 2012-09-06 US US14/343,053 patent/US20140212398A1/en not_active Abandoned
- 2012-09-06 JP JP2014529143A patent/JP6196620B2/ja active Active
- 2012-09-06 BR BR112014005355-3A patent/BR112014005355B1/pt active IP Right Grant
- 2012-09-06 CN CN201280054739.XA patent/CN103930130B/zh active Active
- 2012-09-06 AU AU2012305931A patent/AU2012305931B2/en active Active
-
2014
- 2014-03-19 ZA ZA2014/01993A patent/ZA201401993B/en unknown
-
2017
- 2017-11-29 US US15/825,275 patent/US11324777B2/en active Active
-
2022
- 2022-05-03 US US17/735,146 patent/US12133866B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2014110897A (ru) | Т-клетки центральной памяти против третьей стороны, способы их получения и их применение в трансплантации и лечении заболеваний | |
| RU2011121630A (ru) | Т-клетки центральной памяти против третьей стороны, способы их получения и их применение в трансплантации и лечении заболеваний | |
| JP2013537187A5 (enExample) | ||
| EP2613801B1 (en) | Use of anti third party central memory t cells for anti-leukemia/lymphoma treatment | |
| JP2019520823A5 (enExample) | ||
| WO2012146702A1 (en) | Methods for preparing accessory cells and uses thereof for preparing activated nk cells | |
| Guan et al. | A strategy to reconstitute immunity without GVHD via adoptive allogeneic Tscm therapy | |
| RU2019101826A (ru) | Вето-клетки, полученные из т-клеток памяти | |
| ES2472452B1 (es) | Procedimiento para la selección de linfocitos T antígeno-específicos mediante la identificación de dobletes. | |
| Vianello et al. | Generation of a tissue-engineered thymic organoid | |
| Sattler et al. | GARP as a Tool to Identify Antigen-Specific Human Tregs.: Abstract# B1144 | |
| NZ622749B2 (en) | Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment | |
| HK1187528B (en) | Use of anti third party central memory t cells for anti-leukemia/lymphoma treatment | |
| HK1200099B (en) | Anti third party central memory t cells, methods of producing same and use of same in transplantation and disease treatment |